Quest Diagnostics Inc. DGX benefits from its robust utilization of the Advanced Diagnostics portfolio offerings. The company also expands through strategic acquisitions, completing eight ...

Veracyte VCYT shares have surged 45.6% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 7.6% fall and the S&P 500 composite’s gain of 8.8%. Presently ...

This image-based AI technology can deliver results ... We look forward to MyRisk gene expansion, Precise liquid, FirstGene and MRD in the coming quarters. I will now turn the call over to our ...

Thomas Fuller / SOPA Images / LightRocket via Getty Images Tempus ... for growth in overall testing volume and the launch of our MRD assays, along with modest increases in our technology and ...

Citroen is offering compelling benefits for the Basalt, Aircross, C3, and eC3 for the remainder of March 2025. These ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

MRD, detectable only with molecular techniques, is a key predictor of recurrence. Blinatumomab is already approved for MRD-positive ALL. However, relapses also occur in MRD-negative disease.